in past times several years, the UK has witnessed a revolution in clinical bodyweight‑loss therapies — in the introduction of semaglutide (Wegovy®) to the escalating popularity of tirzepatide (Mounjaro®). Now, another identify is drawing consideration in both equally scientific and general public